From CNBC: 2024-05-16 10:03:34

Roche’s weight loss drug, CT-388, showed promising results in an early-stage trial, with patients losing up to 20% of their weight. The drug mimics gut hormones to suppress appetite, similar to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Roche aims to compete in the $100 billion obesity drug market, dominated by Novo Nordisk and Eli Lilly.



Read more at CNBC: Roche weight loss drug shows promising results in early trial